Immunocore
IMCR
136 hedge funds and large institutions have $1.65B invested in Immunocore in 2026 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 52 increasing their positions, 39 reducing their positions, and 31 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 39
5% more capital invested
Capital invested by funds: $1.58B → $1.65B (+$74.1M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.91% less ownership
Funds ownership: 103.35% → 102.44% (-0.91%)
4% less funds holding
Funds holding: 142 → 136 (-6)
13% less first-time investments, than exits
New positions opened: 27 | Existing positions closed: 31
70% less call options, than puts
Call options by funds: $6.1M | Put options by funds: $20.1M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CP
Caligan Partners
New York
|
+$40.9M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$30M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$21M |
| 4 |
Two Sigma Investments
New York
|
+$18.6M |
| 5 |
B
Braidwell
Stamford,
Connecticut
|
+$15.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$57M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$47.9M |
| 3 |
Fiera Capital (Canada)
Montreal,
Quebec, Canada
|
-$32.6M |
| 4 |
VPC
Vestal Point Capital
New York
|
-$28.6M |
| 5 |
LGM
Logos Global Management
San Francisco,
California
|
-$26.6M |
IMCR Hedge Fund Activity: Q2 2026 in Review
136 of the 8,297 institutional investors tracked by Wall St. Rank reported a position in Immunocore (IMCR) for Q2 2026, worth a combined $1.65B — up 4.7% from $1.58B a quarter earlier.
Sellers outnumbered buyers: 31 funds closed out of IMCR and 27 opened new positions — a net loss of 4 holders — while 39 trimmed existing stakes and 52 added.
The largest buyer was Caligan Partners, opening a new position worth an estimated $40.9M. The largest seller was T. Rowe Price Investment Management, exiting entirely with an estimated $57M sold.
- 136 institutional investors held Immunocore (IMCR) as of Q2 2026, down from 142 in Q1 2026.
- Funds reported $1.65B of Immunocore stock for Q2 2026, up 4.7% quarter-over-quarter.
- 27 funds opened new Immunocore positions in Q2 2026 and 31 closed out, a net change of -4 holders.
- The largest Immunocore buyer in Q2 2026 was Caligan Partners, an estimated $40.9M added.
- The largest Immunocore seller in Q2 2026 was T. Rowe Price Investment Management, an estimated $57M sold.
Based on aggregated 13F filings for Q2 2026.